Close

Canaccord Genuity Reiterates a 'Buy' on Pernix Therapeutics (PTX); Tough Q1, But Thesis Remains Intact

Go back to Canaccord Genuity Reiterates a 'Buy' on Pernix Therapeutics (PTX); Tough Q1, But Thesis Remains Intact